FDA Does Something Good, Okays Clinical Trials of MDMA To Treat PTSD
Now can the DEA remove its Schedule I classification?
Although the Food and Drug Administration has a warped sense of logic when it comes to evaluating the medicinal benefits of cannabis, the morally challenged institution is not completely fucked. The New York Times reports that the federal agency is green-lighting clinical trials of MDMA as a treatment for post-traumatic stress disorder. Long associated with rave culture and orgies, the feel-good party drug often referred to as ecstasy may soon help the thousands of veterans suffering from the ailment. Many of these soldiers, who haven’t been able to find relief through standard prescription medications and therapy, have experienced positive results in some of the limited experiments that have been conducted with MDMA.
According to the paper of record, C.J. Hardin is one of those success stories. He served three tours in Iraq and Afghanistan, but had a tough time readjusting to civilian life when he returned home. “It allowed me to see my trauma without fear or hesitation and finally process things and move forward,” said the vet to the paper.
The U.S. Department of Veterans Affairs estimates that around “8 million adults have PTSD during a given year,” and “about 10 of every 100 women (or 10%) develop PTSD sometime in their lives compared with about 4 of every 100 men (or 4%).”
Like cannabis, the DEA currently categorizes MDMA as a Schedule I drug, which means it has no “accepted medical use and a high potential for abuse,” which is patently untrue, of both substances. If all goes well with the clinical trials, the drug could be available as early as 2021.
Renowned PTSD researcher and doctor Charles Marmar, who heads the psychiatry department at NYU’s Langone School of Medicine, is cautiously optimistic about the recent developments. “If they can keep getting good results, it will be of great use,” he said. “PTSD can be very hard to treat. Our best therapies right now don’t help 30 to 40 percent of people. So we need more options.”